| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
|
Clin Cancer Res
|
2011
|
1.66
|
|
2
|
Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.
|
J Cancer Res Clin Oncol
|
2014
|
1.05
|
|
3
|
Resection of thyroid cancer metastases to the sternum.
|
J Thorac Oncol
|
2009
|
0.96
|
|
4
|
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
|
Clin Cancer Res
|
2006
|
0.95
|
|
5
|
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
|
Clin Pharmacokinet
|
2009
|
0.92
|
|
6
|
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
|
Clin Cancer Res
|
2007
|
0.91
|
|
7
|
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.
|
Clin Cancer Res
|
2002
|
0.90
|
|
8
|
Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
|
Invest New Drugs
|
2003
|
0.89
|
|
9
|
Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
|
Mol Cancer Ther
|
2012
|
0.88
|
|
10
|
A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
|
Anticancer Drugs
|
2008
|
0.87
|
|
11
|
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
|
Liver Int
|
2008
|
0.85
|
|
12
|
Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
|
Cancer Chemother Pharmacol
|
2007
|
0.85
|
|
13
|
Clinical trial designs for targeted agents.
|
Hematol Oncol Clin North Am
|
2002
|
0.78
|
|
14
|
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors.
|
Invest New Drugs
|
2014
|
0.77
|
|
15
|
The effect of formulation and food consumption on the bioavailability of dovitinib (TKI258) in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.77
|